In DLBCL, BL or MCL, OTX015 combined with inhibitors of PI3K (CYH33 [95] or idelalisib [72, 94]), AKT (MK-2206 [94, 96]), or mTOR (everolimus [72, 74, 94, 96] or deforolimus [94]) have indicated greater antitumor activities than BETi mono-treatment. Here, AKT1 is linked to diffuse large B-cell lymphoma.